Effectiveness of Sacubitril Valsartan in Chronic Kidney Disease
Objective To observe the effectiveness of sacubitril valsartan in the management of patients with chronic kidney disease(CKD).Methods A total of 188 CKD patients admitted from April 2022 to September 2023 at our hospital were included and divided into the treatment group(n=94)and the control group(n=94)according to the method of randomized numerical table;the treatment group was given oral sakubatrizol valsartan whereas the control group was given oral valsartan;the baseline data,changes of the related indexes and the incidence of adverse reactions at 6 months of treatment were compared between the 2 groups.Results Compared with the pretreatment,blood potassium was significantly increased,whereas urine protein creatinine ratio(PCR),blood pressure and amino-terminal brain natriuretic precursor(NT-pro BNP)were significantly decreased in the 2 groups at 6 months of treatment,and blood creatinine in the treatment group was more significantly decreased than that in the control group(P＜0.05);blood potassium,urine PCR,NT-ProBNP and diastolic blood pressure in the treatment group were better than those in the control group at 6 months of treatment(P＜0.05);no significant adverse reactions were observed in the 2 groups.Conclusions Compared with valsartan,sacubitril valsartan can significantly reduce the levels of blood creatinine and urine PCR,and delay further progression of renal function,contributing to better control of blood pressure and reducing heart failure markers in patients with CKD.
chronic kidney diseasesacubitril valsartanvalsartanblood creatinineurine protein creatinine ratioblood pressure
万方数据
维普
